* confirmed or suspected cases of sars-cov-2 infection. * has a history of sars, mers, sars-cov-2 infection (self-report, on-site inquiry). * has received covid-19 vaccine (include mrna, recombinant protein vaccines, vector vaccines, inactivated vaccines, etc.) * axillary body temperature \> 37.3 ℃ before vaccination * previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars-cov-2 vaccine have occurred (self-report, on-site inquiry). * history of hospital-diagnosed thrombocytopenia or other coagulation disorder * known immunological impairment or low level with hospital diagnosis * history of uncontrolled epilepsy, other progressive neurological disorders, or guillain-barre syndrome (self-report, on-site inquiry). * known or suspected concomitant serious diseases include: respiratory disease, acute infection or active chronic disease, liver and kidney disease, severe diabetes, malignant tumor, infection or allergic skin disease, hiv infection. * severe cardiovascular disease (cardiopulmonary failure, uncontrolled hypertension, etc.) diagnosed by the hospital, active chronic respiratory disease * live attenuated vaccine is inoculated within 1 month before this vaccination * other vaccines are inoculated within 14 days before this vaccination. * be participating in or plan to participate in other vaccine clinical trials during this study. * contraindications related to vaccination as considered by other investigators.

* confirmed or suspected cases of sars-cov-2 infection. * has a history of sars, mers, sars-cov-2 infection (self-report, on-site inquiry). * has received covid-19 vaccine (include mrna, recombinant protein vaccines, vector vaccines, inactivated vaccines, etc.) * axillary body temperature \> 37.3 ℃ before vaccination * previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars-cov-2 vaccine have occurred (self-report, on-site inquiry). * history of hospital-diagnosed thrombocytopenia or other coagulation disorder * known immunological impairment or low level with hospital diagnosis * history of uncontrolled epilepsy, other progressive neurological disorders, or guillain-barre syndrome (self-report, on-site inquiry). * known or suspected concomitant serious diseases include: respiratory disease, acute infection or active chronic disease, liver and kidney disease, severe diabetes, malignant tumor, infection or allergic skin disease, hiv infection. * severe cardiovascular disease (cardiopulmonary failure, uncontrolled hypertension, etc.) diagnosed by the hospital, active chronic respiratory disease * live attenuated vaccine is inoculated within 1 month before this vaccination * other vaccines are inoculated within 14 days before this vaccination. * be participating in or plan to participate in other vaccine clinical trials during this study. * contraindications related to vaccination as considered by other investigators.

confirmed or suspected cases of sars-cov-2 infection. has a history of sars, mers, sars-cov-2 infection (self-report, on-site inquiry). has received covid-19 vaccine (include mrna, recombinant protein vaccines, vector vaccines, inactivated vaccines, etc.) axillary body temperature > 37.3 ℃ before vaccination previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars-cov-2 vaccine have occurred (self-report, on-site inquiry). history of hospital-diagnosed thrombocytopenia or other coagulation disorder known immunological impairment or low level with hospital diagnosis history of uncontrolled epilepsy, other progressive neurological disorders, or guillain-barre syndrome (self-report, on-site inquiry). known or suspected concomitant serious diseases include: respiratory disease, acute infection or active chronic disease, liver and kidney disease, severe diabetes, malignant tumor, infection or allergic skin disease, hiv infection. severe cardiovascular disease (cardiopulmonary failure, uncontrolled hypertension, etc.) diagnosed by the hospital, active chronic respiratory disease live attenuated vaccine is inoculated within 1 month before this vaccination other vaccines are inoculated within 14 days before this vaccination. be participating in or plan to participate in other vaccine clinical trials during this study. contraindications related to vaccination as considered by other investigators.

confirmed or suspected cases of sars-cov-2 infection. has a history of sars, mers, sars-cov-2 infection (self-report, on-site inquiry). has received covid-19 vaccine (include mrna, recombinant protein vaccines, vector vaccines, inactivated vaccines, etc.) axillary body temperature > 37.3 ℃ before vaccination previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars-cov-2 vaccine have occurred (self-report, on-site inquiry). history of hospital-diagnosed thrombocytopenia or other coagulation disorder known immunological impairment or low level with hospital diagnosis history of uncontrolled epilepsy, other progressive neurological disorders, or guillain-barre syndrome (self-report, on-site inquiry). known or suspected concomitant serious diseases include: respiratory disease, acute infection or active chronic disease, liver and kidney disease, severe diabetes, malignant tumor, infection or allergic skin disease, hiv infection. severe cardiovascular disease (cardiopulmonary failure, uncontrolled hypertension, etc.) diagnosed by the hospital, active chronic respiratory disease live attenuated vaccine is inoculated within 1 month before this vaccination other vaccines are inoculated within 14 days before this vaccination. be participating in or plan to participate in other vaccine clinical trials during this study. contraindications related to vaccination as considered by other investigators.